Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (SHA:603392)

SHA:603392 Ratios and Metrics

Market cap in millions CNY. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Feb 5, 2026	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	52,927	89,141	95,280	114,799	134,459	87,383
Market Cap Growth	-38.37%	-6.44%	-17.00%	-14.62%	53.87%	-
Enterprise Value	48,356	84,105	90,027	108,497	134,052	86,784
Last Close Price	41.86	70.46	74.78	89.12	107.37	69.72
PE Ratio	-	839.09	76.37	24.24	66.52	129.07
Forward PE	-	48.64	17.29	20.47	76.21	97.59
PS Ratio	29.48	39.70	17.29	10.26	23.38	37.12
PB Ratio	4.31	7.16	7.40	9.14	29.47	33.86
P/TBV Ratio	4.70	7.59	7.82	9.53	32.20	37.55
P/FCF Ratio	-	-	251.96	35.85	212.03	1123.62
P/OCF Ratio	321.61	251.04	61.96	27.78	79.94	186.63
EV/Sales Ratio	26.93	37.46	16.34	9.70	23.31	36.86
EV/EBITDA Ratio	-	-	57.00	20.09	57.44	107.25
EV/EBIT Ratio	-	-	66.00	20.61	59.91	119.75
EV/FCF Ratio	-84.05	-	238.07	33.88	211.39	1115.90
Debt / Equity Ratio	0.03	0.03	0.02	0.02	0.06	0.03
Debt / EBITDA Ratio	-	-	0.19	0.05	0.12	0.10
Debt / FCF Ratio	-	-	0.82	0.09	0.45	1.00
Asset Turnover	0.12	0.15	0.35	0.96	1.09	0.83
Inventory Turnover	1.12	0.98	1.22	1.64	1.71	1.49
Quick Ratio	3.76	3.72	3.34	3.20	1.67	1.86
Current Ratio	4.26	4.16	3.86	3.50	1.96	2.39
Return on Equity (ROE)	-2.70%	0.86%	9.80%	56.79%	58.22%	32.77%
Return on Assets (ROA)	-3.04%	-1.30%	5.34%	28.27%	26.51%	15.98%
Return on Invested Capital (ROIC)	-9.36%	-4.27%	18.83%	103.82%	79.47%	41.71%
Return on Capital Employed (ROCE)	-5.70%	-2.50%	10.50%	41.30%	47.80%	27.10%
Earnings Yield	-0.63%	0.12%	1.31%	4.13%	1.50%	0.78%
FCF Yield	-1.09%	-0.60%	0.40%	2.79%	0.47%	0.09%
Dividend Yield	-	-	0.43%	0.80%	0.09%	0.13%
Payout Ratio	-	386.11%	72.73%	2.69%	5.58%	0.24%
Buyback Yield / Dilution	-3.21%	-5.37%	-0.86%	-1.55%	-2.96%	-8.71%
Total Shareholder Return	-3.21%	-5.37%	-0.43%	-0.75%	-2.87%	-8.59%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.